The Journal of Allergy and Clinical Immunology
Volume 125, Issue 2 , Pages 349-356.e13 , February 2010

Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma

  • Margaret M. Kelly, MB, PhD, FRCPC

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Firestone Institute for Respiratory Health, Department of Pathology and Molecular Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, Alberta, Canada
    • These authors contributed equally to this work.
    • ,
  • Terence M. O'Connor, MB, FRCPI

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • These authors contributed equally to this work.
    • ,
  • Richard Leigh, MB, PhD, FRCPC

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Joceline Otis, MLT

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Carol Gwozd, MLT

      Affiliations

    • Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, Alberta, Canada
    • ,
  • Gail M. Gauvreau, PhD

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Jack Gauldie, PhD

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Pathology and Molecular Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Paul M. O'Byrne, MB, FRCPC, FRCPI

      Affiliations

    • Firestone Institute for Respiratory Health, Department of Medicine, St Joseph's Healthcare and McMaster University Medical Center, McMaster University, Hamilton, Ontario, Canada
    • Corresponding Author InformationAddress for reprints: Paul M. O'Byrne, MB, FRCPC, HSC 3 W10, McMaster University, 1200 Main St West, Hamilton, Ontario L8N 3Z5, Canada.

Received 8 February 2009 ,Revised 2 September 2009 ,Accepted 8 September 2009.

References 

  1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–178
  2. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary Report 2007. J Allergy Clin Immunol. 2007;120(suppl):S94–S138
  3. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219–224
  4. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481–1488
  5. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405–1411
  6. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392–1397
  7. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844
  8. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–136
  9. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Lofdahl CG, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J. 1999;14:1038–1043
  10. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol. 2006;117:563–570
  11. Sears MR, Boulet LP, Laviolette M, FitzGerald JM, Bai TR, Kaplan A, et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J. 2008;31:982–989
  12. Cockcroft DW. Airway responsiveness. In:  Barnes PJ,  Grunstein MM,  Leff AR,  Woolcock AJ editor. Asthma. Philadelphia: Lippencott-Raven; 1997;p. 1253–1266
  13. Gauvreau GM, Doctor J, Watson RM, Jordana M, O'Byrne PM. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med. 1996;154:1267–1271
  14. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002;166:1212–1217
  15. Wiggs BR, Bosken C, Pare PD, James A, Hogg JC. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;145:1251–1258
  16. Bousquet J, Jeffery PK, Busse WB, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720–1745
  17. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J. 2007;30:134–155
  18. Bates JH, Cojocaru A, Haverkamp HC, Rinaldi LM, Irvin CG. The synergistic interactions of allergic lung inflammation and intratracheal cationic protein. Am J Respir Crit Care Med. 2008;177:261–268
  19. O'Byrne P. Asthma pathogenesis and allergen-induced late responses. J Allergy Clin Immunol. 1998;102(suppl):S85–S89
  20. Gizycki MJ, Adelroth E, Rogers A, O'Byrne P, Jeffery PK. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol. 1997;16:664–673
  21. Schurch W, Seemayer TA, Gabbiani G. The myofibroblast: a quarter century after its discovery. Am J Surg Pathol. 1998;22:141–147
  22. Kariyawasam HH, Aizen M, Barkans J, Robinson DS, Kay AB. Remodeling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma. Am J Respir Crit Care Med. 2007;175:896–904
  23. O'Connor TM, Kelly MM, Leigh R, Otis J, Gauvreau GM, Gauldie J, et al. Anti-inflammatory effects of inhaled budesonide combined with formoterol after allergen challenge in subjects with atopic asthma. [abstract] Am J Respir Crit Care Med. 2006;3:A75
  24. O'Connor TM, Kelly MM, Leigh R, Otis J, Gauvreau GM, Gauldie J, et al. Additional anti-inflammatory effects of inhaled budesonide/formoterol over inhaled budesonide in subjects with atopic asthma. [abstract] Eur Respir J. 2006;28:441S
  25. Kelly MM, O'Connor TM, Leigh R, Otis J, Gauvreau GM, Gauldie J, et al. Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myofibroblasts. [abstract] Eur Respir J. 2008;30:P903
  26. Kelly MM, Chakir J, Vethanayagam D, Boulet LP, Laviolette M, Gauldie J, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest. 2006;130:741–753
  27. Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE. Reproducibility and comparison of responses to inhaled histamine and methacholine. Thorax. 1978;33:705–710
  28. Giembycz MA, Kaur M, Leigh R, Newton R. A holy grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol. 2008;153:1090–1104
  29. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924–930
  30. Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, Gratziou C, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J. 1999;14:275–282
  31. Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol. 2007;119:322–327
  32. Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, et al. An antiiinflammatory effect of salmeterol, a long-acting beta2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med. 1999;160:1493–1499
  33. Baouz S, Giron-Michel J, Azzarone B, Giuliani M, Cagnoni F, Olsson S, et al. Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol. 2005;17:1473–1481
  34. Kaur M, Chivers JE, Giembycz MA, Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol. 2008;73:203–214
  35. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(suppl):S28–S38
  36. Pare PD, Wiggs BR, James A, Hogg JC, Bosken C. The comparative mechanics and morphology of airways in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;143:1189–1193
  37. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis. 1993;147:405–410
  38. Woodruff PG, Dolganov GM, Ferrando RE, Donnelly S, Hays SR, Solberg OD, et al. Hyperplasia of smooth muscle in mild/moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med. 2004;169:1001–1006
  39. Katoh K, Kano Y, Amano M, Onishi H, Kaibuchi K, Fujiwara K. Rho-kinase–mediated contraction of isolated stress fibers. J Cell Biol. 2001;153:569–584
  40. Bogatkevich GS, Tourkina E, Abrams CS, Harley RA, Silver RM, Ludwicka-Bradley A. Contractile activity and smooth muscle alpha-actin organization in thrombin-induced human lung myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2003;285:L334–L343
  41. Ward C, Walters H. Airway wall remodelling: the influence of corticosteroids. Curr Opin Allergy Clin Immunol. 2005;5:43–48
  42. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med. 2003;167:1360–1368
  43. Madison JM. Migration of airway smooth muscle cells. Am J Respir Cell Mol Biol. 2003;29:8–11
  44. Roth M, Johnson PR, Borger P, Bihl MP, Rudiger JJ, King GG, et al. Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med. 2004;351:560–574
  45. Bonacci JV, Harris T, Wilson JW, Stewart AG. Collagen-induced resistance to glucocorticoid anti-mitogenic actions: a potential explanation of smooth muscle hyperplasia in the asthmatic remodelled airway. Br J Pharmacol. 2003;138:1203–1206
  46. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol. 2005;116:544–549
  47. Moreno RH, Hogg JC, Pare PD. Mechanics of airway narrowing. Am Rev Respir Dis. 1986;133:1171–1180
  48. James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis. 1989;139:242–246
  49. Wiggs BR, Moreno R, Hogg JC, Hilliam C, Pare PD. A model of the mechanics of airway narrowing. J Appl Physiol. 1990;69:849–860
  50. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol. 1993;74:2771–2781
  51. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148:1220–1225

 Supported by an unrestricted grant from AstraZeneca, Lund, Sweden.

 Disclosure of potential conflict of interest: T. M. O'Connor receives research support from AstraZeneca Ireland. R. Leigh is a consultant for AstraZeneca Canada, GlaxoSmithKline, Novartis Pharmaceuticals Canada, and Boehringer-Ingelheim Canada; is on the speakers' bureau for AstraZeneca Canada, GlaxoSmithKline, and Novartis Pharmaceuticals Canada; and receives research support from Novartis Pharmaceuticals Canada, MedImmune, Ception, Merck-Frosst Canada, Schering-Plough, and Bayer. G. M. Gauvreau receives grant support from Schering-Plough and MedImmune. P. M. O'Byrne is on the Advisory Board for AstraZeneca, GlaxoSmithKline, Topigen, Wyeth, and Schering-Plough; is on the speakers' bureau for AstraZeneca and GlaxoSmithKline; and receives research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth, Schering-Plough, and Alexion. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01340-2

doi: 10.1016/j.jaci.2009.09.011

The Journal of Allergy and Clinical Immunology
Volume 125, Issue 2 , Pages 349-356.e13 , February 2010

Article Tools

* Image Usage & Resolution